Corvus Pharmaceuticals, Inc.
CRVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001626971
No open-market purchases or sales by Corvus Pharmaceuticals, Inc. insiders were filed in the last 90 days; 173 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Corvus Pharmaceuticals, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 37 | 52 | +15 |
| Shares | 20.8M | 19.5M | −1.30M (−6.3%) |
| Value | $18.9M | $44.6M | +$25.7M (+136.0%) |
New holders (22)
Institutions that held Corvus Pharmaceuticals, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Samlyn Capital, LLC | 2,105,930 | $4.82M | 0.08% |
| Marshall Wace, LLP | 299,140 | $685.0K | 0.00% |
| Towerview LLC | 205,000 | $469.4K | 0.31% |
| MYDA Advisors LLC | 100,000 | $229.0K | 0.09% |
| Cornercap Investment Counsel Inc | 97,248 | $222.7K | 0.04% |
| Goldman Sachs Group Inc | 94,311 | $216.0K | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 84,368 | $193.2K | 0.00% |
| Dimensional Fund Advisors LP | 58,112 | $133.1K | 0.00% |
| Jane Street Group, LLC | 35,118 | $80.4K | 0.00% |
| Bank of New York Mellon Corp | 21,219 | $48.6K | 0.00% |
| Squarepoint Ops LLC | 17,082 | $39.1K | 0.00% |
| Charles Schwab Investment Management Inc | 15,668 | $35.9K | 0.00% |
| Cubist Systematic Strategies, LLC | 15,552 | $35.6K | 0.00% |
| Tucker Asset Management LLC | 12,871 | $29.5K | 0.01% |
| Simplex Trading, LLC | 11,529 | $26.0K | 0.00% |
| Invesco Ltd. | 10,945 | $25.1K | 0.00% |
| Difesa Capital Management, LP | 10,000 | $22.9K | 0.06% |
| Bank of America Corp | 5,079 | $11.6K | 0.00% |
| Northwest Capital Management Inc | 3,397 | $7.78K | 0.00% |
| Natixis | 800 | $1.83K | 0.00% |
| Rhumbline Advisers | 791 | $1.81K | 0.00% |
| NewSquare Capital LLC | 220 | $504 | 0.00% |
Sold out (7)
Institutions that held Corvus Pharmaceuticals, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Millennium Management LLC | 2,029,423 | $1.85M |
| Discovery Capital Management, LLC | 548,727 | $499.3K |
| LMR Partners LLP | 30,000 | $27.3K |
| Baader Bank INC | 24,911 | $17.7K |
| Mercer Global Advisors Inc | 10,550 | $10.0K |
| Envestnet Asset Management Inc | 10,500 | $9.55K |
| TCI Wealth Advisors, Inc. | 500 | $455 |